Vibrant Therapeutics, an AI-driven macromolecular drug discovery and development platform, has completed raising 100 million yuan ($15 million) in a new funding round.
Matrix Partners China has led the funding with the participation of Sequoia Capital China alongside existing backer Redhill Capital.
